Anesta Actiq
Executive Summary
Company files amendment to NDA May 4 for oral transmucosal fentanyl citrate in the treatment of chronic pain. The amendment contains a reanalysis of the adverse events and dosing profiles data, more information on stability and packaging, and an expansion and clarification of Anesta's proposed risk-management plan. Anesta received a "not approvable" letter in November for the NDA submitted a year earlier ("The Pink Sheet" Nov. 24, 1997, T&G-11)
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth